Considered with the central role and high expression of RP105/MD-1 in adipose macrophages (Watanabe et al., 2012), myocardial cells (Shuai et al., 2020), cardiomyoblast cells (Qin et al., 2019), and smooth muscle cells (Wezel et al., 2016), this complex had been suggested as a possible therapeutic target in reducing chronic inflammatory of diabetes mellitus (Watanabe et al., 2012, 2013; Nagai et al., 2013), rheumatoid arthritis (Bruhl et al., 2015), and SLE (Yang et al., 2018a). Here, LY86 is linked to systemic lupus erythematosus.